The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Igalmi
Dexmedetomidine · DEXMEDETOMIDINE 120 ug/1 · Film · Sublingual · BioXcel Therapeutics, Inc.
NDC 81092-1120-01 · 10 POUCH in 1 CARTON / 1 FILM in 1 POUCH · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$108.78per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$67.27per unitBioXcel Therapeutics, Inc. · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$105.00
Reported to Texas DSHS · 2026 annual filing · BioXcel Therapeutics, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2024)
$311,445
105 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- ARx, LLCUnited Statesmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $3,185.56 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA215390
- TE code
- —
- Approval date
- Apr 5, 2022
- Patents / exclusivity
- 28 patents, 2 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | M-82 | Nov 19, 2028 |
| exclusivity | M-82 | Nov 19, 2028 |
| patent | 11806334 | Jan 12, 2043 |
| patent | 12364683 | Jan 12, 2043 |
| patent | 12364683 | Jan 12, 2043 |
| patent | 11998528 | Jan 12, 2043 |
| patent | 11998528 | Jan 12, 2043 |
| patent | 11806334 | Jan 12, 2043 |
| patent | 12090140 | Jan 12, 2043 |
| patent | 12090140 | Jan 12, 2043 |
| patent | 12138247 | Jan 12, 2043 |
| patent | 12138247 | Jan 12, 2043 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Dexmedetomidine (Film)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| BioXcel Therapeutics, Inc. | DEXMEDETOMIDINE 120 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| BioXcel Therapeutics, Inc. | DEXMEDETOMIDINE 180 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Igalmi — NDC 81092-1120-01," retrieved September 3, 2026, https://drugdashboards.com/drug/81092112001.
Free to cite with attribution — see how the data is put together.